| abstract |
The fusion protein, especially recombinant, comprising domain (a) which is a functional fragment of the soluble hTRAIL protein sequence starting with an amino acid in a position not less than hTRAIL95 or a sequence that has at least 70% homology ; and domain (b) which is a sequence of the pro-apoptotic effector peptide, wherein the sequence of domain (b) binds at C-terminal and / or N-terminal of domain (a); the fusion protein has activity against cancer; the nucleotide sequence encoding the fusion protein, expression vector and host cell for the preparation of the fusion protein, and the use of the fusion protein for the treatment of cancer diseases. |